RYAN Q2 2026: Organic Growth Slips to 6.7%, Net Income Drops 13.1%

What happened

Ryan Specialty reported second-quarter 2026 revenue of $916.6 million, a 7.2% year-over-year increase, but organic growth decelerated to 6.7% from 7.1% a year ago, and net income fell 13.1% — the full extent of the profit decline was not disclosed. The organic growth rate now sits firmly in the bear-case range of 6–8%, confirming that the softening property cycle and increased direct placement by retailers are eroding the core franchise. With the stock already down 36% from its early-2025 highs, this print will likely force a reassessment of the growth trajectory and further pressure the multiple. Management’s strategy of heavy talent investment has yet to yield operating leverage, and the elevated net-debt-to-EBITDA ratio of 4.88x leaves little room for earnings weakness. Taken together, the results shift the narrative from a temporary soft patch to a potentially structural slowdown.

Implication

The Q2 print validates the bear scenario outlined in the prior analysis, indicating a potential shift from a growth-at-a-reasonable-price story to a value trap. Persistent organic growth below 8% and declining net income may force management to rein in aggressive hiring and M&A, further dampening near-term growth prospects. The stock’s elevated leverage (4.88x net debt/EBITDA) leaves limited cushion if earnings continue to degrade. Absent a sharp reversal in property pricing or a successful acceleration of producer productivity, the valuation could drift toward the $32 bear case over the next six months. Investors should watch the upcoming earnings call for any guide-down or acknowledgment of structural headwinds.

Thesis delta

The thesis shifts from a wait-and-see posture to an actively bearish tilt, as Q2 results confirm the organic growth deceleration feared in the bear case. The probability that Ryan Specialty can sustain the 9–11% organic growth needed to support the prior WAIT valuation has diminished, raising the risk of a downward re-rating. The investment case now hinges on whether management can engineer a quick recovery in organic growth and margins, which appears increasingly challenging given the cycle.